GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Concord Drugs Ltd (BOM:538965) » Definitions » Cyclically Adjusted Revenue per Share

Concord Drugs (BOM:538965) Cyclically Adjusted Revenue per Share : ₹79.37 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Concord Drugs Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Concord Drugs's adjusted revenue per share for the three months ended in Dec. 2023 was ₹12.720. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹79.37 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-21), Concord Drugs's current stock price is ₹38.71. Concord Drugs's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was ₹79.37. Concord Drugs's Cyclically Adjusted PS Ratio of today is 0.49.

During the past 10 years, the highest Cyclically Adjusted PS Ratio of Concord Drugs was 0.65. The lowest was 0.44. And the median was 0.50.


Concord Drugs Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Concord Drugs's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Drugs Cyclically Adjusted Revenue per Share Chart

Concord Drugs Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Concord Drugs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 79.37

Competitive Comparison of Concord Drugs's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Concord Drugs's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Concord Drugs's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Concord Drugs's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Concord Drugs's Cyclically Adjusted PS Ratio falls into.



Concord Drugs Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Concord Drugs's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=12.72/152.9243*152.9243
=12.720

Current CPI (Dec. 2023) = 152.9243.

Concord Drugs Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 12.938 91.425 21.641
201406 12.994 94.103 21.116
201409 13.515 96.780 21.355
201412 14.189 96.780 22.420
201503 1.479 97.163 2.328
201506 16.165 99.841 24.760
201509 16.453 101.753 24.727
201512 18.305 102.901 27.204
201603 19.401 102.518 28.940
201606 18.360 105.961 26.497
201609 19.224 105.961 27.744
201612 12.738 105.196 18.517
201703 29.556 105.196 42.966
201706 28.953 107.109 41.338
201709 5.108 109.021 7.165
201712 6.860 109.404 9.589
201803 26.832 109.786 37.375
201806 16.314 111.317 22.412
201809 15.403 115.142 20.457
201812 12.514 115.142 16.620
201903 17.547 118.202 22.701
201906 14.867 120.880 18.808
201909 14.967 123.175 18.582
201912 12.309 126.235 14.911
202003 14.715 124.705 18.045
202006 20.911 127.000 25.179
202009 18.897 130.118 22.209
202012 9.436 130.889 11.025
202103 9.545 131.771 11.077
202106 23.227 134.084 26.491
202109 11.161 135.847 12.564
202112 15.311 138.161 16.947
202203 17.749 138.822 19.552
202206 14.042 142.347 15.085
202209 15.887 144.661 16.794
202212 15.483 145.763 16.244
202303 11.188 146.865 11.650
202306 9.705 150.280 9.876
202309 8.028 151.492 8.104
202312 12.720 152.924 12.720

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Concord Drugs  (BOM:538965) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Concord Drugs's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=38.71/79.37
=0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 10 years, the highest Cyclically Adjusted PS Ratio of Concord Drugs was 0.65. The lowest was 0.44. And the median was 0.50.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Concord Drugs Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Concord Drugs's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Concord Drugs (BOM:538965) Business Description

Industry
Traded in Other Exchanges
N/A
Address
3-11-451, L B Nagar, Hayatnagar Mandal, Hyderabad, TG, IND, 500074
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers. Geographically, it operates only in India.

Concord Drugs (BOM:538965) Headlines

No Headlines